GLP-1 Drugs and Eating Disorders: Why Doctors Are Sounding the Alarm Right Now
A new report surfaces a growing clinical blind spot: what happens when GLP-1 medications meet active or historical eating disorders?
Good — I have solid material to work with. Let me now write the article using the sourced information I've gathered.
GLP-1 Drugs and Eating Disorders: Why Doctors Are Sounding the Alarm Right Now
A Washington Post report published May 23, 2026 is putting a sharp spotlight on something clinicians have been quietly worried about for months: people with active or historical eating disorders are getting on GLP-1 medications — and the medical community doesn't have a clean answer for what happens next.
This isn't a fringe concern. It's a collision between two of the most prevalent health issues of our time, and the research is still catching up.
What the Concern Actually Is
GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) work, in large part, by dramatically suppressing appetite. For someone with obesity and no eating disorder history, that's the point.
But for someone with anorexia nervosa, a history of restrictive eating, or active purging behaviors, that same appetite suppression can reinforce dangerous patterns — making it easier to restrict, harder to notice hunger cues, and potentially masking warning signs that a provider would normally pick up on.
MedlinePlus (NIH) describes eating disorders as serious mental health conditions that "affect your body's ability to get proper nutrition" and can lead to heart and kidney problems — or death. They're not a lifestyle choice, and they don't disappear because someone is also living with obesity. The two conditions overlap more than most people assume.
NPR covered this same tension in February 2026, noting that GLP-1 drugs "can complicate life for people with disordered eating" — and both National Geographic and the University of Cincinnati have separately flagged prescriber anxiety around this exact patient population.
The Science Is Genuinely Complicated
Here's where it gets nuanced: GLP-1s don't have a single, predictable effect on eating disorders. The type of disorder matters enormously.
For binge eating disorder (BED) — the most common eating disorder in the U.S., per MedlinePlus — there's actually a case for cautious optimism. A 2023 retrospective cohort study published in Obesity Pillars found semaglutide showed promise in treating binge eating disorder, with patients reporting reduced episodes. A 2024 paper in the Journal of Endocrinology specifically examined the emerging role of GLP-1 in binge eating, suggesting the drug's effects on reward pathways in the brain may reduce compulsive eating urges.
But for restrictive disorders — anorexia nervosa chief among them — the concern runs in the opposite direction entirely. Blunting hunger in someone who already struggles to eat enough is a medically serious risk. And a 2024 review in CNS Drugs on pharmacological treatment of binge eating disorder and its comorbidities underscores just how complex the pharmacotherapy landscape is even for the "easier" eating disorder cases.
The FDA's label for Wegovy lists severe gastrointestinal side effects — nausea, vomiting, diarrhea — as among the most common reactions, per the FDA-approved Wegovy prescribing information. For someone already restricting food or purging, those side effects aren't just uncomfortable — they can worsen malnutrition and electrolyte imbalances that are already dangerous.
The Screening Gap Nobody Is Talking About Enough
The pivotal clinical trials that got these drugs approved largely excluded people with active eating disorders. That means real-world prescribers are now navigating situations the trial data simply doesn't cover.
A 2024 review in Expert Opinion on Pharmacotherapy on managing binge eating disorder with pharmacotherapy points to how inconsistently eating disorders are screened for in obesity treatment settings — a gap that becomes more consequential as GLP-1 prescriptions scale into the tens of millions.
The New York Post reported in January 2026 on first-person accounts of people saying GLP-1 drugs "brought our eating disorders back" — a pattern clinicians say they're increasingly hearing in practice, even if the formal research hasn't yet quantified it.
What Responsible Prescribing Looks Like Here
Doctors aren't saying GLP-1s are off-limits for anyone with an eating disorder history. The picture is more specific than that.
What they are saying is that a thorough psychiatric and behavioral screen before prescribing matters — and that ongoing monitoring for signs of restriction, purging, or disordered cognition around food needs to happen throughout treatment. This is especially true given how quickly these medications can change a person's relationship with hunger.
MedlinePlus notes that eating disorders are treatable, but treatment requires professional support — not just a prescription adjustment. For anyone navigating both obesity and an eating disorder history, the right answer is almost certainly a team approach: prescriber, therapist, and ideally a dietitian who specializes in eating disorders, not just weight management.
What This Means for You
- If you have a current or past eating disorder, be direct with your prescriber before starting a GLP-1. This isn't a reason to be disqualified — it's information they need to monitor you safely.
- If you're already on a GLP-1 and noticing you're restricting food, skipping meals, or feeling anxious about eating, flag it immediately. Don't wait for your next scheduled appointment.
- The research on GLP-1s and eating disorders is still developing. The nuance matters: binge eating disorder and restrictive disorders are not the same risk profile, and your care should reflect that difference.
Not medical advice. Talk to your prescriber about your situation — especially if you have any history of disordered eating.
